Paclitaxel continues to be a drug compound of interest stemming from characterization shown by Mastropaolo, D., et al. in Figure , to improving total synthesis in recent years by Iliyama, S., et al. , and Hu, Y., et al. . Future work will focus on developing AI breakthroughs for challenging drug synthesis and biosynthesis problems. This will occur through the incorporation of large and complex volumes of data created by human researchers that is too difficult for prior AI. The end goal is to implement structured and unstructured data responses into human workflows to solve the hardest problems in less time.